World Journal of
Pharmaceutical and Life Sciences

USE OF LETROZOLE FOR INFERTILITY IN THE POLYCYSTIC OVARY SYNDROME

Rokeya Ferdousey*, Rehana Parvin, Shahin Rahman Chowdhury and Dr. Morshed Nasir

ABSTRACT

Introduction: The polycystic ovary syndrome is a common cause of infertility. Letrozole, a third generation aromatase inhibitor, is now considered as the best alternative of clomiphene citrate for the infertility treatment in women with the polycystic ovary syndrome. Objective: To observed effect of letrozole therapy in infertile women with polycystic ovary syndrome. Methodology: In this cross-sectional study we enrolled 310 infertile women aged 20-35 years diagnosed as polycystic ovary syndrome. Participants who had normal uterine cavity and sperm concentration of at least 20 million/ml of her husband were prescribed letrozole for 6 months. Medication was discontinued when pregnancy was confirmed and participants were followed untill delivery. Results: After 6 months treatment 125 (40.5%) patient was conceived. Live birth was 65 (20.9%) of 310 subjects. Among pregnancies multiple (twin) birth was 18 (5.7%). First trimester pregnancy loss was 61(19.5%). After having 6 months of therapy there was no pregnancy in 185 (59.5%) patients. Conclusions: Letrozole is safe and cost effective medicine in achieving live birth in infertile women with polycystic ovary syndrome.

[Full Text Article]   [Download Certificate]